These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32339438)

  • 61. Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations.
    Karslioglu French E; Nikitski AV; Yip L; Nikiforova MN; Nikiforov YE; Carty SE
    Endocr Relat Cancer; 2022 Aug; 29(8):467-473. PubMed ID: 35609001
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma.
    Zhao L; Dias-Santagata D; Sadow PM; Faquin WC
    Cancer Cytopathol; 2017 May; 125(5):323-331. PubMed ID: 28192645
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?
    Hudson TJ; Pusztaszeri MP; Hier MP; Forest VI; Yang JW; Payne RJ
    J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):12. PubMed ID: 36774522
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in the pediatric age group.
    Rossi ED; Mehrotra S; Kilic AI; Toslak IE; Lim-Dunham J; Martini M; Fadda G; Lombardi CP; Larocca LM; Barkan GA
    Cancer Cytopathol; 2018 Jan; 126(1):27-35. PubMed ID: 29024469
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Causes of misdiagnoses by thyroid fine-needle aspiration cytology (FNAC): our experience and a systematic review.
    Zhu Y; Song Y; Xu G; Fan Z; Ren W
    Diagn Pathol; 2020 Jan; 15(1):1. PubMed ID: 31900180
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The influence of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) resection diagnosis on the false-positive thyroid cytology rate relates to quality assurance thresholds and the application of NIFTP criteria.
    Ohori NP; Wolfe J; Carty SE; Yip L; LeBeau SO; Berg AN; Schoedel KE; Nikiforov YE; Seethala RR
    Cancer Cytopathol; 2017 Sep; 125(9):692-700. PubMed ID: 28678437
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis.
    Vardarli I; Tan S; Görges R; Krämer BK; Herrmann K; Brochhausen C
    Endocr Connect; 2024 Jul; 13(7):. PubMed ID: 38771544
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
    Bose S; Sacks W; Walts AE
    Adv Anat Pathol; 2019 Mar; 26(2):114-123. PubMed ID: 30664001
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
    Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Value of Negative Diagnosis in Thyroid Fine-Needle Aspiration: a Retrospective Study with Histologic Follow-Up.
    Abi-Raad R; Prasad M; Baldassari R; Schofield K; Callender GG; Chhieng D; Adeniran AJ
    Endocr Pathol; 2018 Sep; 29(3):269-275. PubMed ID: 29949024
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The first Canadian experience with the Afirma® gene expression classifier test.
    Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact on the reclassification of thyroid nodules.
    Amendoeira I; Maia T; Sobrinho-Simões M
    Endocr Relat Cancer; 2018 Apr; 25(4):R247-R258. PubMed ID: 29439059
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of the modification of the diagnostic criteria in the 2017 Bethesda System for Reporting Thyroid Cytopathology: a report of a single institution in Japan.
    Higuchi M; Hirokawa M; Kanematsu R; Tanaka A; Suzuki A; Yamao N; Hayashi T; Kuma S; Miyauchi A
    Endocr J; 2018 Dec; 65(12):1193-1198. PubMed ID: 30282887
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
    Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
    Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of Ancillary Techniques in Thyroid Cytology Specimens.
    Nishino M; Krane JF
    Acta Cytol; 2020; 64(1-2):40-51. PubMed ID: 30947167
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis.
    Bongiovanni M; Giovanella L; Romanelli F; Trimboli P
    Thyroid; 2019 Feb; 29(2):222-228. PubMed ID: 30426887
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Monitoring Outcomes of Indeterminate Thyroid Nodules and Predictive Capabilities of Molecular Testing.
    Garrett S; Millay D; Pierre J; Pluta N; Russo C; Neelon D; Bauer E; Hoang T; Orestes M
    Ann Otol Rhinol Laryngol; 2024 Jul; ():34894241264380. PubMed ID: 39075822
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Johnson DN; Sadow PM
    Hum Pathol; 2018 Dec; 82():32-38. PubMed ID: 30146440
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests.
    Valderrabano P; Leon ME; Centeno BA; Otto KJ; Khazai L; McCaffrey JC; Russell JS; McIver B
    Eur J Endocrinol; 2016 May; 174(5):621-9. PubMed ID: 26903551
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    Sfreddo HJ; Koh ES; Zhao K; Swartzwelder CE; Untch BR; Marti JL; Roman BR; Dublin J; Wang RS; Xia R; Cohen JM; Xu B; Ghossein R; Givi B; Boyle JO; Tuttle RM; Fagin JA; Wong RJ; Morris LGT
    Thyroid; 2024 Apr; 34(4):450-459. PubMed ID: 38407967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.